Yttrium-90/indium-111-DOTA-peptide-chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer

Sally J. Denardo, Carol M Richman, Desiree S. Goldstein, Sui Shen, Qansy Sajlako, David L. Kukis, Claude F. Meares, Aina Yuan, Jeanna L Welborn, Gerald L Denardo

Research output: Contribution to journalArticle

78 Scopus citations

Abstract

Background: Radioimmunotherapy (RIT) using 131I-Chimeric L6 (ChL6) antibody has shown therapeutic promise for patients with breast cancer. To enhance this potential a novel immunoconjugate was developed that targets adenocarcinomas like breast cancer and tightly binds yttrium-90 (90Y) for therapy and indium-111 (111In) for imaging. The radioimmunoconjugate consists of a macrocyclic chelator (DOTA) linked to ChL6 by a catabolizable peptide. 90Y-DOTA-peptide-ChL6 was designed to minimize the radiation dose to critical normal tissues, thereby improving the therapeutic index. materials and Methods: Three patients with incurable metastatic breast cancer received 90Y/111In-DOTA-peptide-ChL6 for 5 phamacokinetics/dosimetry studies and one of these patients also received 2 therapy doses. Quantitative imaging of 111In and in vitro assay of 90Y and 111In in blood urine and bone marrow samples were obtained. Results: 90Y/111In-DOTA-peptide-ChL6 was prepared at high purity and was stable in vivo. Assays of bone marrow revealed no evidence for escape of 90Y or 111In from the chelate. 111In provided comparable pharmacokinetics, as did tracer and therapeutic doses of radiommunoconjugates. One patient that received 2 therapeutic doses of 90Y-DOTA-peptide-ChL6 showed regression of tumors and tumor markers. Toxicities were relatively minor and no anti-globulin response developed despite 5 immunoconjugate infusions. Conclusions: This first study in patients of radioimmimoconjugates with a catabolizable linker between the metal chelator and the antibody confirmed that these novel 90Y/111In-DOTA-peptideChL6 radiommunoconjugates have significant potential. Tracer doses of 111In-DOTA-peptide-ChL6 for imaging predicted the behavior of therapeutic doses of 90Y-DOTA-peptideChL6. The latter radioimmunoconjugate induced regression of tumors and tumor markers without significant toxicity. When compared to earlier 131I-ChL6 dosimetry, 90Y-DOTA-peptide-ChL6 provided a therapeutic index several times better.

Original languageEnglish (US)
Pages (from-to)1735-1744
Number of pages10
JournalAnticancer Research
Volume17
Issue number3 B
StatePublished - 1997

    Fingerprint

Keywords

  • Antibody
  • Breast cancer
  • Immunoconjugate
  • Metabolizable linker
  • Radioimmunotherapy
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this